2 weeks Ago By ABMN Staff
Canada Pension Plan Investment Board purchased a new stake in shares of Adaptive Biotechnologies Co. ( NASDAQ:ADPT – Free Report ) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund purchased 27,200 shares of the company’s stock, valued at approximately $98,000.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Manchester Capital Management LLC bought a new stake in shares of Adaptive Biotechnologies during the first quarter worth $32,000. Rothschild Investment LLC bought a new stake in Adaptive Biotechnologies during the 2nd quarter worth $36,000.
MQS Management LLC bought a new stake in Adaptive Biotechnologies during the 2nd quarter worth $36,000. Pinnacle Wealth Planning Services Inc. acquired a new position in Adaptive Biotechnologies in the 1st quarter worth about $46,000.
Finally, First Trust Direct Indexing L.P. bought a new position in Adaptive Biotechnologies in the first quarter valued at about $47,000.
99.17% of the stock is owned by institutional investors. Adaptive Biotechnologies Stock Up 2.
0 % Shares of NASDAQ:ADPT opened at $5.00 on Friday. The firm has a market cap of $736.
84 million, a P/E ratio of -3.36 and a beta of 1.42.
Adaptive Biotechnologies Co. has a 12-month low of $2.28 and a 12-month high of $5.
73. The business has a fifty day simple moving average of $4.50 and a 200 day simple moving average of $3.
70. Wall Street Analysts Forecast Growth Separately, JPMorgan Chase & Co. boosted their price target on Adaptive Biotechnologies from $5.
00 to $6.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock.
According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $6.40.
Get Our Latest Analysis on Adaptive Biotechnologies Adaptive Biotechnologies Company Profile ( Free Report ) Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. Featured Stories Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.
com's FREE daily email newsletter ..
